The arrival of effective weight loss medication is the largest change to this landscape in a long time, and any publication about non-surgical body treatment that does not address it is avoiding the subject. We will try to describe it carefully, because it is a subject where careless writing does damage.
What these medicines are
GLP-1 receptor agonists mimic a hormone involved in appetite regulation and gastric emptying. They were developed in the context of type 2 diabetes and are now also used in the management of overweight and obesity, in defined circumstances, on prescription.
In England, guidance from NICE sets out the circumstances in which specific medicines in this area are recommended, including an appraisal of semaglutide for managing overweight and obesity. These are clinical decisions made with a prescriber who is managing your care, and this publication is not the place to make them.
What is relevant here is scale. The weight change achievable through this route, in appropriate patients, is of a different order from anything a non-surgical body device has ever offered. That is a factual comparison, and it matters for how this category should be understood.
The first change: the total mass question now has an answer
We wrote in a separate article that the commonest mismatch in this market is somebody with a total mass question buying a distribution treatment. For a long time, part of the reason that happened was that the total mass question did not have a satisfying clinical answer available to most people.
That has changed for some people. Whether it is right for any individual is a clinical matter, and access is variable, and the medicines have side effects and contraindications and are not appropriate for everyone. What is different is that there is now a route, and it runs through a prescriber rather than through a clinic selling a device.
The implication for this category is uncomfortable and worth stating: a person whose real question was about total mass now has somewhere better to take it, and a clinic that continues to sell them a device course is doing something that was always mismatched and is now visibly so.
The second change: new concerns, mostly not addressed by this category
Substantial weight loss, by any route, changes more than the number on a scale. Skin that accommodated a larger volume does not necessarily retract to fit a smaller one. Facial and body volume change in ways people often find unexpected. Areas that were previously smooth can become loose.
These concerns are real, they are common, and they are now the subject of considerable marketing. A great deal of the non-surgical body category has repositioned itself towards them.
The difficulty is that most of this category does not resolve them. Skin laxity is principally a question of tissue quantity and structure, and the devices in this market act on tissue quality at best. We set out what can and cannot be reached in skin laxity after weight loss, and the answer for significant laxity is generally surgical or nothing.
“Our body treatment programme is the perfect companion to your weight loss injection.”
What would have to be true
- That the treatments offered address the concerns that arise during weight loss, which are principally skin laxity and changes in volume.
- That treating an area whose fat content is actively changing produces a result that will hold.
- That combining an unregulated cosmetic programme with a prescribed medicine has been considered clinically.
What is actually established
- Non-surgical devices produce modest localised changes in the pinchable layer.
- The concerns most often reported during substantial weight loss are skin laxity and volume change, which those devices largely do not address.
- Treating an area while its fat content is changing means the result cannot be attributed or relied upon.
This is a positioning claim rather than a clinical one. Selling a distribution treatment alongside a medicine that is changing total mass means treating a moving target, and the concerns that actually arise during weight loss are mostly not the ones these devices address.
The timing point, which is practical
If you are losing weight, this is not the time to buy a localised body treatment.
The reason is straightforward. Any change in the treated area over the following months will be the combined result of the weight change and the treatment, and there is no way to separate them. You cannot assess whether the treatment did anything, the clinic cannot demonstrate that it did, and if the area improves the treatment will be credited with work that the weight loss did.
Beyond assessment, there is a practical point: a treatment reducing cell number in an area is being applied to an area that is going to change substantially anyway. Waiting until weight is stable is the sequence that makes sense, and it is the sequence a clinic with your interests in mind would suggest.
If you are taking a GLP-1 medicine
- Your weight is changing, which means any localised treatment is being applied to a moving target and its result cannot be judged.
- The sensible sequence, if you want a localised treatment at all, is to wait until weight is stable rather than to treat during the change.
- Tell any aesthetic practitioner what you are taking. It is relevant clinical information, and a practitioner who does not ask is not assessing you.
- The concerns most likely to arise are skin laxity and volume change, and most of this category does not resolve either.
- Obtaining these medicines outside the regulated supply chain carries real risk, and the MHRA has issued warnings about products bought that way.
- The medicine is a clinical matter for the prescriber who is managing you, not for a clinic selling a device.
None of this is an argument for or against the medication. It is a set of practical implications for anyone who is taking one and is also considering a cosmetic treatment.
A word about supply
These are prescription medicines and they should be obtained through the regulated supply chain, with a prescriber who has assessed you. The MHRA has issued warnings about products obtained outside that chain, including falsified products, and the risks involved in injecting something whose contents are unknown do not need elaborating.
If you experience a suspected adverse reaction to a medicine, you can report it yourself through the Yellow Card scheme without needing anybody's permission.
How we are trying to write about this
This subject invites two failures. One is to treat weight loss medication as a moral shortcut, which is not a medical position and not ours. The other is to treat it as an answer to every question, which it is not: it is a prescription medicine with indications, contraindications, side effects and an evidence base, used within a clinical relationship.
What we will say is what this publication says about everything: the question is whether the intervention being offered matches the question being asked. For somebody whose question is total mass, a device course was never the answer and is now obviously not. For somebody whose question is a small persistent deposit on a stable body, nothing about this changes. And for somebody who has lost a great deal of weight and is now unhappy with loose skin, the category is being marketed at them and largely cannot help, which is the situation we would most like readers to recognise before paying.